MBSW 2016: Pharmaceutical Statistics pp 27-43

# Sample Size Consideration for Equivalent Test of Tier-1 Quality Attributes for Analytical Biosimilarity Assessment

• Tianhua Wang
• Yi Tsong
• Meiyu Shen
Conference paper
Part of the Springer Proceedings in Mathematics & Statistics book series (PROMS, volume 218)

## Abstract

FDA recommends a stepwise approach for obtaining the totality-of-the-evidence for assessing biosimilarity between a proposed biosimilar product and its corresponding reference biologic product being considered (US Food and Drug Administration.: Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. US Food and Drug Administration, Silver Spring, 2015 [6]). The stepwise approach starts with analytical studies for assessing similarity in critical quality attributes (CQAs), which are relevant to clinical outcomes. For critical quality attributes that are most relevant to clinical outcomes (Tier 1 CQAs), FDA requires equivalence testing to be performed for similarity assessment, based on an equivalence acceptance criteria. In practice, the number of Tier 1 CQAs might be greater than one, and should be no more than four. The number of biosimilar lots is often recommended to be no less than 10, and the ratio between the reference product sample size and biosimilar product sample size is recommended within the range from $$2/3$$ to $$3/2$$ (US Food and Drug Administration.: Guidance for industry: Statistical Approaches to Evaluate Analytical Similarity. US Food and Drug Administration, Silver Spring, 2017 [7]). Accordingly, we derive the formulas for the power calculation for the sample size for analytical similarity assessment based on the equivalence testing currently used in analytical biosimilar assessment (Tsong et al. J Biopharm Stat 27:197–205, (2017)[10]).

## Keywords

Analytical similarity Equivalence testing Sample size Analytical power function Correlation coefficient Satterthwaite approximation Sparse grid

## References

1. 1.
Burdick, R.K., Thomas, N., Cheng, A.: Statistical considerations in demonstrating cmc analytical similarity for a biosimilar product. Stat. Biopharm. Res. 9(3), 249–257 (2017)
2. 2.
Chen, Y.M., Weng, Y.T., Dong, X., Tsong, Y.: Wald tests for variance-adjusted equivalence assessment with normal endpoints. J. Biopharm. Stat. 27(2), 308–316 (2017)
3. 3.
Chow, S.C., Song, F., Bai, H.: Sample size requirement in analytical studies for similarity assessment. J. Biopharm. Stat. 27(2), 233–238 (2017)
4. 4.
Dong, X., Bian, Y., Tsong, Y., Wang, T.: Exact test-based approach for equivalence test with parameter margin. J. Biopharm. Stat. 27(2), 317–330 (2017)
5. 5.
Dong, X., Weng, Y.T., Tsong, Y.: Adjustment for unbalanced sample size for analytical biosimilar equivalence assessment. J. Biopharm. Stat. 27(2), 220–232 (2017)
6. 6.
Joarder, A.H.: Moments of the product and ratio of two correlated chi-square variables. Stat. Pap. 50(3), 581–592 (2009)
7. 7.
Smolyak, S.: Quadrature and interpolation formulas for tensor products of certain classes of functions. Soviet Math. Dokl. 4, 240–243. American Mathematical Society (1963)Google Scholar
8. 8.
Tsong, Y., Dong, X., Shen, M.: Development of statistical methods for analytical similarity assessment. J. Biopharm. Stat. 27(2), 197–205 (2017)
9. 9.
US Food and Drug Administration.: Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. Silver Spring, MD., US Food and Drug Administration (2015)Google Scholar
10. 10.
US Food and Drug Administration.: Guidance for industry: Statistical Approaches to Evaluate Analytical Similarity. Silver Spring, MD., US Food and Drug Administration (2017)Google Scholar
11. 11.
Weng, Y.T., Tsong, Y., Shen, M., and Wang, C.: Improved Wald test for equivalence assessment of analytical biosimilarity. Int. J. of Clinical Biostat. And Biometrics. (2018) SubmittedGoogle Scholar